Activation of HCA2 regulates microglial responses to alleviate neurodegeneration in LPS-induced in vivo and in vitro models
Tóm tắt
Previous studies have shown a close association between an altered immune system and Parkinson's disease (PD). Neuroinflammation inhibition may be an effective measure to prevent PD. Recently, numerous reports have highlighted the potential of hydroxy-carboxylic acid receptor 2 (HCA2) in inflammation-related diseases. Notably, the role of HCA2 in neurodegenerative diseases is also becoming more widely known. However, its role and exact mechanism in PD remain to be investigated. Nicotinic acid (NA) is one of the crucial ligands of HCA2, activating it. Based on such findings, this study aimed to examine the effect of HCA2 on neuroinflammation and the role of NA-activated HCA2 in PD and its underlying mechanisms. For in vivo studies, 10-week-old male C57BL/6 and HCA2−/− mice were injected with LPS in the substantia nigra (SN) to construct a PD model. The motor behavior of mice was detected using open field, pole-climbing and rotor experiment. The damage to the mice's dopaminergic neurons was detected using immunohistochemical staining and western blotting methods. In vitro, inflammatory mediators (IL-6, TNF-α, iNOS and COX-2) and anti-inflammatory factors (Arg-1, Ym-1, CD206 and IL-10) were detected using RT-PCR, ELISA and immunofluorescence. Inflammatory pathways (AKT, PPARγ and NF-κB) were delineated by RT-PCR and western blotting. Neuronal damage was detected using CCK8, LDH, and flow cytometry assays. HCA2−/− increases mice susceptibility to dopaminergic neuronal injury, motor deficits, and inflammatory responses. Mechanistically, HCA2 activation in microglia promotes anti-inflammatory microglia and inhibits pro-inflammatory microglia by activating AKT/PPARγ and inhibiting NF-κB signaling pathways. Further, HCA2 activation in microglia attenuates microglial activation-mediated neuronal injury. Moreover, nicotinic acid (NA), a specific agonist of HCA2, alleviated dopaminergic neuronal injury and motor deficits in PD mice by activating HCA2 in microglia in vivo. Niacin receptor HCA2 modulates microglial phenotype to inhibit neurodegeneration in LPS-induced in vivo and in vitro models.
Tài liệu tham khảo
Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055–66. https://doi.org/10.1016/S0140-6736(09)60492-X.
McClymont SA, Hook PW, Soto AI, Reed X, Law WD, Kerans SJ, Waite EL, Briceno NJ, Thole JF, Heckman MG, et al. Parkinson-Associated SNCA enhancer variants revealed by open chromatin in mouse dopamine neurons. Am J Hum Genet. 2018;103:874–92. https://doi.org/10.1016/j.ajhg.2018.10.018.
Gonzalez-Latapi P, Marotta N, Mencacci NE. Emerging and converging molecular mechanisms in dystonia. J Neural Transm (Vienna). 2021;128:483–98. https://doi.org/10.1007/s00702-020-02290-z.
Pirooznia SK, Rosenthal LS, Dawson VL, Dawson TM. Parkinson disease: translating insights from molecular mechanisms to neuroprotection. Pharmacol Rev. 2021;73:33–97. https://doi.org/10.1124/pharmrev.120.000189.
Vazquez-Velez GE, Zoghbi HY. Parkinson’s disease genetics and pathophysiology. Annu Rev Neurosci. 2021;44:87–108. https://doi.org/10.1146/annurev-neuro-100720-034518.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8:382–97. https://doi.org/10.1016/S1474-4422(09)70062-6.
Kanthasamy A, Jin H, Charli A, Vellareddy A, Kanthasamy A. Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms. Pharmacol Ther. 2019;197:61–82. https://doi.org/10.1016/j.pharmthera.2019.01.001.
Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022. https://doi.org/10.1038/s41577-022-00684-6.
Tan JK, McKenzie C, Marino E, Macia L, Mackay CR. Metabolite-sensing G protein-coupled receptors-facilitators of diet-related immune regulation. Annu Rev Immunol. 2017;35:371–402. https://doi.org/10.1146/annurev-immunol-051116-052235.
Zeman M, Vecka M, Perlik F, Stankova B, Hromadka R, Tvrzicka E, Sirc J, Hrib J, Zak A. Pleiotropic effects of niacin: Current possibilities for its clinical use. Acta Pharm. 2016;66:449–69. https://doi.org/10.1515/acph-2016-0043.
Chen G, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine. 2018;30:317–25. https://doi.org/10.1016/j.ebiom.2018.03.030.
Gong Y, Jin X, Yuan B, Lv Y, Yan G, Liu M, Xie C, Liu J, Tang Y, Gao H, et al. G Protein-Coupled Receptor 109A Maintains the Intestinal Integrity and Protects Against ETEC Mucosal Infection by Promoting IgA Secretion. Front Immunol. 2020;11:583652. https://doi.org/10.3389/fimmu.2020.583652.
Guo W, Liu J, Sun J, Gong Q, Ma H, Kan X, Cao Y, Wang J, Fu S. Butyrate alleviates oxidative stress by regulating NRF2 nuclear accumulation and H3K9/14 acetylation via GPR109A in bovine mammary epithelial cells and mammary glands. Free Radic Biol Med. 2020;152:728–42. https://doi.org/10.1016/j.freeradbiomed.2020.01.016.
Fu SP, Wang JF, Xue WJ, Liu HM, Liu BR, Zeng YL, Li SN, Huang BX, Lv QK, Wang W, et al. Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation. 2015;12:9. https://doi.org/10.1186/s12974-014-0230-3.
Fangmann D, Theismann EM, Turk K, Schulte DM, Relling I, Hartmann K, Keppler JK, Knipp JR, Rehman A, Heinsen FA, et al. Targeted microbiome intervention by microencapsulated delayed-release niacin beneficially affects insulin sensitivity in humans. Diabetes Care. 2018;41:398–405. https://doi.org/10.2337/dc17-1967.
Hanson J, Gille A, Offermanns S. Role of HCA(2) (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol Ther. 2012;136:1–7. https://doi.org/10.1016/j.pharmthera.2012.06.003.
Guo W, Liu J, Li W, Ma H, Gong Q, Kan X, Cao Y, Wang J, Fu S. Niacin Alleviates Dairy Cow Mastitis by Regulating the GPR109A/AMPK/NRF2 Signaling Pathway. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21093321.
Moutinho M, Puntambekar SS, Tsai AP, Coronel I, Lin PB, Casali BT, Martinez P, Oblak AL, Lasagna-Reeves CA, Lamb BT, et al. The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer’s disease. Sci Transl Med. 2022;14:l7634. https://doi.org/10.1126/scitranslmed.abl7634.
Wakade C, Giri B, Malik A, Khodadadi H, Morgan JC, Chong RK, Baban B. Niacin modulates macrophage polarization in Parkinson’s disease. J Neuroimmunol. 2018;320:76–9. https://doi.org/10.1016/j.jneuroim.2018.05.002.
He D, Fu S, Zhou A, Su Y, Gao X, Zhang Y, Huang B, Du J, Liu D. Camptothecin Regulates Microglia Polarization and Exerts Neuroprotective Effects via Activating AKT/Nrf2/HO-1 and Inhibiting NF-kappaB Pathways In Vivo and In Vitro. Front Immunol. 2021;12:619761. https://doi.org/10.3389/fimmu.2021.619761.
Huang B, Liu J, Meng T, Li Y, He D, Ran X, Chen G, Guo W, Kan X, Fu S, et al. Polydatin Prevents Lipopolysaccharide (LPS)-Induced Parkinson’s Disease via Regulation of the AKT/GSK3beta-Nrf2/NF-kappaB Signaling Axis. Front Immunol. 2018;9:2527. https://doi.org/10.3389/fimmu.2018.02527.
Liu B, Huang B, Hu G, He D, Li Y, Ran X, Du J, Fu S, Liu D. Isovitexin-mediated regulation of microglial polarization in lipopolysaccharide-induced neuroinflammation via activation of the CaMKKbeta/AMPK-PGC-1alpha Signaling Axis. Front Immunol. 2019;10:2650. https://doi.org/10.3389/fimmu.2019.02650.
Li Z, McCafferty KJ, Judd RL. Role of HCA2 in Regulating Intestinal Homeostasis and Suppressing Colon Carcinogenesis. Front Immunol. 2021;12:606384. https://doi.org/10.3389/fimmu.2021.606384.
Graff EC, Fang H, Wanders D, Judd RL. Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2. Metabolism. 2016;65:102–13. https://doi.org/10.1016/j.metabol.2015.10.001.
Rahman M, Muhammad S, Khan MA, Chen H, Ridder DA, Muller-Fielitz H, Pokorna B, Vollbrandt T, Stolting I, Nadrowitz R, et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun. 2014;5:3944. https://doi.org/10.1038/ncomms4944.
Masini D, Kiehn O. Targeted activation of midbrain neurons restores locomotor function in mouse models of parkinsonism. Nat Commun. 2022;13:504. https://doi.org/10.1038/s41467-022-28075-4.
Sassone J, Serratto G, Valtorta F, Silani V, Passafaro M, Ciammola A. The synaptic function of parkin. Brain. 2017;140:2265–72. https://doi.org/10.1093/brain/awx006.
Morsali D, Bechtold D, Lee W, Chauhdry S, Palchaudhuri U, Hassoon P, Snell DM, Malpass K, Piers T, Pocock J, et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain. 2013;136:1067–82. https://doi.org/10.1093/brain/awt041.
Nolan YM, Sullivan AM, Toulouse A. Parkinson’s disease in the nuclear age of neuroinflammation. Trends Mol Med. 2013;19:187–96. https://doi.org/10.1016/j.molmed.2012.12.003.
Courtney R, Landreth GE. LXR regulation of brain cholesterol: from development to disease. Trends Endocrinol Metab. 2016;27:404–14. https://doi.org/10.1016/j.tem.2016.03.018.
Ruiz de Azua I, Lutz B. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues. Cell Mol Life Sci. 2019;76:1341–63. https://doi.org/10.1007/s00018-018-2994-6.
Park TI, Smyth LCD, Aalderink M, Woolf ZR, Rustenhoven J, Lee K, Jansson D, Smith A, Feng S, Correia J, et al. Routine culture and study of adult human brain cells from neurosurgical specimens. Nat Protoc. 2022;17:190–221. https://doi.org/10.1038/s41596-021-00637-8.
Zhao M, Jiang XF, Zhang HQ, Sun JH, Pei H, Ma LN, Cao Y, Li H. Interactions between glial cells and the blood-brain barrier and their role in Alzheimer’s disease. Ageing Res Rev. 2021;72:101483. https://doi.org/10.1016/j.arr.2021.101483.
Liu H, Han Y, Wang T, Zhang H, Xu Q, Yuan J, Li Z. Targeting microglia for therapy of Parkinson’s disease by using biomimetic ultrasmall nanoparticles. J Am Chem Soc. 2020;142:21730–42. https://doi.org/10.1021/jacs.0c09390.
Van den Broek B, Pintelon I, Hamad I, Kessels S, Haidar M, Hellings N, Hendriks JJA, Kleinewietfeld M, Brone B, Timmerman V, et al. Microglial derived extracellular vesicles activate autophagy and mediate multi-target signaling to maintain cellular homeostasis. J Extracell Vesicles. 2020;10:e12022. https://doi.org/10.1002/jev2.12022.
Bok E, Chung YC, Kim KS, Baik HH, Shin WH, Jin BK. Modulation of M1/M2 polarization by capsaicin contributes to the survival of dopaminergic neurons in the lipopolysaccharide-lesioned substantia nigra in vivo. Exp Mol Med. 2018;50:1–14. https://doi.org/10.1038/s12276-018-0111-4.
Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2016;173:649–65. https://doi.org/10.1111/bph.13139.
Zhao SC, Ma LS, Chu ZH, Xu H, Wu WQ, Liu F. Regulation of microglial activation in stroke. Acta Pharmacol Sin. 2017;38:445–58. https://doi.org/10.1038/aps.2016.162.
Aaboe Jorgensen M, Ugel S, Linder Hubbe M, Carretta M, Perez-Penco M, Weis-Banke SE, Martinenaite E, Kopp K, Chapellier M, Adamo A, et al. Arginase 1-based immune modulatory vaccines induce anticancer immunity and synergize with Anti-PD-1 Checkpoint Blockade. Cancer Immunol Res. 2021;9:1316–26. https://doi.org/10.1158/2326-6066.CIR-21-0280.
Jarrold J, Davies CC. PRMTs and Arginine Methylation: Cancer’s Best-Kept Secret? Trends Mol Med. 2019;25:993–1009. https://doi.org/10.1016/j.molmed.2019.05.007.
Zhou D, Huang C, Lin Z, Zhan S, Kong L, Fang C, Li J. Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways. Cell Signal. 2014;26:192–7. https://doi.org/10.1016/j.cellsig.2013.11.004.
Pajares M, Aui IR, Manda G, Bosca L, Cuadrado A. Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells. 2020. https://doi.org/10.3390/cells9071687.
Ahmad J, Haider N, Khan MA, Md S, Alhakamy NA, Ghoneim MM, Alshehri S, Sarim Imam S, Ahmad MZ, Mishra A. Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery. Biochem Pharmacol. 2022;195:114849. https://doi.org/10.1016/j.bcp.2021.114849.
Cenci MA, Skovgard K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson’s disease. Neuropharmacology. 2022;210:109027. https://doi.org/10.1016/j.neuropharm.2022.109027.
Muller T. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2020;16:403–14. https://doi.org/10.1080/17425255.2020.1750596.